Navigation Links
Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
Date:10/21/2013

BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients. Under a 2011 collaborative development agreement, Inovio's affiliate, VGX International Inc. (KSE: 011000), is fully funding and conducting the study at multiple sites in Korea. Inovio is also planning to evaluate this hepatitis C (HCV) vaccine in additional clinical studies in the U.S. beginning in 2014.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "More effective antiviral drugs have changed the prognosis for patients with hepatitis C; however, treatment failures remain and combination with an immunotherapeutic approach could make the difference for many patients. In preclinical studies, Inovio's HCV immunotherapy has shown to generate powerful T cell responses in the liver, which could be important in clearing HCV-infected liver cells.  We have already shown in published clinical studies that our vaccines generate best-in-class T-cell responses. In this study, the effects of Inovio's HCV immunotherapy will be directly tested in patients who have previously failed standard drug therapies. We look forward to entering the hepatitis C treatment arena, which is one of the fastest-developing markets in healthcare, with a projected value of $20 billion by the end of the decade."  

This study is a multi-center, open-label, dose-escalating phase I trial in which 18 subjects will be divided into three groups and given four monthly vaccinations of 1 mg, 3 mg and 6 mg doses of VGX-6150, respectively. Individuals with chronic HCV who failed previous standard of care therapy with pegylated interferon and ribavirin or triple therapy with standard of care and direct-acting antiviral agents
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
2. Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
3. Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
4. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
5. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
6. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
7. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
8. Inovio Pharmaceuticals Responds to Market Activity
9. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
10. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
11. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
(Date:9/19/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 19, ... company focused on cloud-based drug design and development, ... strategy. The company,s mission is to design new ... Phase 1 and 2 partners to further their ... enhance its portfolio investments. To support this business ...
(Date:9/19/2014)... DUBLIN , Sept. 19, 2014 Research ... "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) ... For the purposes of this report, the human ... The human microbiome market is expected to be ... grow at a CAGR of 22.3% within the forecast period ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) will ... community on Thursday, December 8, 2011 from 8:00 a.m. ... New York City.  Members of BioMarin,s management team and ... product portfolio and advancements in the research and development ...
... 17, 2011 Eli Lilly and Company (NYSE: ... more than $4 million in additional funding to the ... to continue its early phase drug discovery efforts focused ... against tuberculosis, including multidrug-resistant strains known as MDR-TB. In ...
Cached Medicine Technology:BioMarin to Host a Research and Development Day on December 8th 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 3Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 4
(Date:9/21/2014)... 21, 2014 To accommodate the ever-growing ... and provide more trendy items. Recently, the company has ... offering the new and elegant wedding gowns, Angeldress.co.uk wants ... they need in an easy way. Its high quality ... rates, from 12% off to 62% off. , Online ...
(Date:9/21/2014)... experienced review website in the global market, Top10BestSEOHosting.com, has ... that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and Bluehost are ... been a boom in websites in recent years, and ... the number of web hosting companies that offer a ... (Virtual Private Server) is the method of partitioning a ...
(Date:9/21/2014)... 2014 Developers and plugin specialist of ... a new transition plugin entitled Transpack Vol. 3 from ... quality transitions that will add a level of professionalism ... of Pixel Film Studios. “Blurring the line between professional ... changer.” , Transpack Vol. 3 returns with over 85 ...
(Date:9/21/2014)... According to latest National Vital Statistics Reports ... 1966 (10.5 births per 1,000 women in 2013). Since 2000, ... steadily by 2 percent per year. The birth rate for ... and over) also rose, the first such increase since 2008. ... times as many first births to women aged 35 and ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses ... newly announced evening cocktail dresses . As a ... outfits are very popular among worldwide customers. Now, all ... (up to 65 percent off). , All UWDress.com’s ... occasion outfits for the global clients. The company is ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2
... Free Fertility ... see a fertility specialist. With a few clicks of a mouse, women receive a personalized ... ... Schumann, President of the Consumer Services Division of IntegraMed announced today the launch of Free ...
... , ... to Spearhead Company,s Quality, Regulatory and Compliance Matters , ... Panama City, Fla. (PRWEB) April 26, 2010 -- ... the appointment of Samuel Patton as the company’s chief quality and regulatory officer. He ...
... ... to help businesses in Maryland, Virginia and the District of Columbia determine if their leases ... important lease clauses. CA Commercial is also offering “New Lease Review” for Franchise systems to ... ...
... increase the risk of breast cancer among white women have ... Cancer , a peer-reviewed journal of the American Cancer ... how breast cancer risk factors differ among ethnic and racial ... and racial groups, but the reasons behind these differences are ...
... ... special celebrity appearance with launching her latest and greatest new hot fitness machine, ... Hit, the Ab Circle Pro, JNL,s Ab Circle Mini is half the size, ... the same results. Her Management Team has confirmed the following day for her ...
... ... ... launch of two new websites, it’s new and improved consumer site www.thewileyprotocol.com . ... ,These sites are the result of one year of analysis, design, and programming. Our ...
Cached Medicine News:Health News:Fertility Check Educates Women About Infertility; IntegraMed Launches Interactive Assessment Tool 2Health News:Fertility Check Educates Women About Infertility; IntegraMed Launches Interactive Assessment Tool 3Health News:iSirona Appoints Chief Quality and Regulatory Officer to Oversee Quality Initiatives 2Health News:CA Commercial Realty Partners Announces “Free Lease Review for local Businesses" 2Health News:Breast cancer risk factors differ among races 2Health News:Global Premiere: Jennifer Nicole Lee, Super Fitness Model & Mega Brand, Reveals Ab Circle Mini on HSN's World Launch 2Health News:Global Premiere: Jennifer Nicole Lee, Super Fitness Model & Mega Brand, Reveals Ab Circle Mini on HSN's World Launch 3Health News:New Wiley Protocol Web Site Launches 2Health News:New Wiley Protocol Web Site Launches 3
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
This is a 3D transducer for endovaginal imaging in OB/GYN....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Medicine Products: